Paper Details

  1. Home
  2. Paper Details

Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy.

Author: LiuHui, MiaoWenchun, TaoShi, YuanXianggui, ZhuWeiguo

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Dual inhibition of histone deacetylase (HDAC) and Bruton's tyrosine kinase (BTK) may be a promising treatment option for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after failure of CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy. This case report describes a successful outcome in an elderly patient with R/R DLBCL who achieved complete remission after receiving this dual inhibition treatment.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Failure to CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), is an emerging clinical problem. There is no consensus on the treatment for these patients and treatment remains empirical. CASE R...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226330/

データ提供：米国国立医学図書館（NLM）

A New Hope for Refractory Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is a type of cancer that affects the lymphatic system. This case report highlights the successful treatment of a patient with refractory DLBCL, a type of cancer that is resistant to conventional therapies. This study explores a unique combination therapy that offers hope for patients with refractory DLBCL.

Dual Inhibition: A Promising New Approach

The case report showcases the success of a dual-inhibition strategy that targets both HDAC and BTK, two crucial enzymes involved in cancer cell growth and survival. This novel approach offers hope for patients who have not responded to traditional treatments, including CAR-T therapy.

A New Oasis in the Desert of Cancer Treatment

This research is like a refreshing oasis in the vast desert of cancer treatment. It offers a new avenue of hope for patients with refractory DLBCL.

Dr.Camel's Conclusion

The successful treatment of refractory DLBCL using dual inhibition of HDAC and BTK is a groundbreaking development. This research is a testament to the ingenuity and perseverance of medical professionals in the fight against cancer.

Date :
  1. Date Completed 2022-06-28
  2. Date Revised 2022-07-16
Further Info :

Pubmed ID

35757723

DOI: Digital Object Identifier

PMC9226330

Related Literature

Article Analysis
・Effects of zanubrutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.